High-risk prostate cancer: is androgen deprivation monotherapy still appropriate?

• 来源期刊: 亚洲男性学杂志（英文版）
• 年，卷（期）: 2012,（3）
• 页码范围: 419-420
• 页数: 2页
• 语种: 英文
• DOI: 10.1038/aja.2011.182

摘要

The optimal management of high-risk prostate cancer,defined by tumor stage T3a or higher,a Gleason score of 8-10 or a prostate-specific antigen level ＞20 ng ml-1,is unclear,and continues to be a source of substantial controversy.1 Though now much less common with the widespread adoption of prostate-specific antigen screening,it remains important as a cause of prostate cancer death.In large clinical trials,it has already been established that androgen deprivation therapy (ADT) added to external beam radiation therapy improves overall survival when compared to radiation alone.2,3 Although this clarifies the best approach for men choosing radiation therapy,it leaves open the question of the value of androgen deprivation monotherapy (i.e.,as primary therapy).